<html>
<head>PUBMED IDs for DENND2D</head>
<body bgcolor='#C5F0F2'><h1>DENND2D</h1><a href='https://pubmed.ncbi.nlm.nih.gov/18677770/'>Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay.</a> August 5  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/23182661/'>Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D.</a> July 16  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24098497/'>Concurrent gene signatures for han chinese breast cancers.</a> July 30  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24189587/'>Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma.</a> August 19  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24317529/'>Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus.</a> September 4  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/26783084/'>Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D.</a> December 27  2016<br></body></html>
